{
    "score": [
        1.0
    ],
    "extracted": [
        0
    ],
    "abstract": [
        "concert pharmaceuticals downgraded by bidaskclub to hold ."
    ],
    "id": "1006715.train",
    "article": [
        "concert pharmaceuticals was downgraded by stock analysts at bidaskclub from a `` buy '' rating to a `` hold '' rating in a research report issued to clients and investors on tuesday . a number of other brokerages have also recently commented on cnce . thestreet upgraded shares of concert pharmaceuticals from a `` c + '' rating to a `` b - '' rating in a research report on monday , january 8th . mizuho cut shares of concert pharmaceuticals from a `` buy '' rating to a `` neutral '' rating and set a $ 23.00 target price on the stock . ",
        "in a research report on friday . ubs group set a $ 34.00 target price on shares of concert pharmaceuticals and gave the stock a `` buy '' rating in a research report on tuesday , december 19th . stifel nicolaus reiterated a `` buy '' rating and issued a $ 27.00 target price on shares of concert pharmaceuticals in a research report on friday . finally , valuengine cut shares of concert pharmaceuticals from a `` hold '' rating to a `` sell '' rating in a research report on tuesday . one analyst has rated the stock with a sell rating , three have assigned a hold rating and four have assigned a buy rating to the company . ",
        "concert pharmaceuticals has an average rating of `` hold '' and a consensus target price of $ 24.33 . shares of concert pharmaceuticals traded down $ 0.91 during trading hours on tuesday , reaching $ 19.24 . 1,445,695 shares of the company were exchanged , compared to its average volume of 738,490 . the stock has a market cap of $ 458.87 , a pe ratio of 5.17 and a beta of 1.67 . concert pharmaceuticals has a one year low of $ 8.61 and a one year high of $ 30.71 . concert pharmaceuticals last issued its earnings results on thursday , november 9th . ",
        "the biotechnology company reported eps for the quarter , missing analysts ' consensus estimates of by . concert pharmaceuticals had a negative return on equity of 51.48 % and a net margin of 62.31 % . equities research analysts anticipate that concert pharmaceuticals will post 4.1 eps for the current fiscal year . in other concert pharmaceuticals news , insider value fund l. p. biotechnology sold 1,282,856 shares of the business 's stock in a transaction dated tuesday , december 19th . the shares were sold at an average price of $ 26.65 , for a total value of $ 34,188,112.40 . ",
        "the transaction was disclosed in a legal filing with the sec , which is available at this hyperlink . also , insider value fund l. p. biotechnology acquired 331,916 shares of the firm 's stock in a transaction on thursday , october 19th . the stock was purchased at an average price of $ 15.84 per share , for a total transaction of $ 5,257,549.44 . the disclosure for this purchase can be found here . 10.10 % of the stock is currently owned by insiders . several hedge funds have recently added to or reduced their stakes in the business . ",
        "the manufacturers life insurance company increased its position in shares of concert pharmaceuticals by 1.9 % in the second quarter . the manufacturers life insurance company now owns 15,052 shares of the biotechnology company 's stock valued at $ 210,000 after acquiring an additional 287 shares during the period . rhumbline advisers increased its position in shares of concert pharmaceuticals by 8.0 % in the second quarter . rhumbline advisers now owns 20,253 shares of the biotechnology company 's stock valued at $ 283,000 after acquiring an additional 1,500 shares during the period . bank of new york mellon corp increased its position in shares of concert pharmaceuticals by 1.5 % in the second quarter . ",
        "bank of new york mellon corp now owns 125,996 shares of the biotechnology company 's stock valued at $ 1,757,000 after acquiring an additional 1,852 shares during the period . teachers advisors llc increased its position in shares of concert pharmaceuticals by 11.1 % in the second quarter . teachers advisors llc now owns 34,373 shares of the biotechnology company 's stock valued at $ 480,000 after acquiring an additional 3,446 shares during the period . finally , principal financial group inc. . increased its position in shares of concert pharmaceuticals by 3.0 % in the third quarter . principal financial group inc. . ",
        "now owns 118,600 shares of the biotechnology company 's stock valued at $ 1,749,000 after acquiring an additional 3,500 shares during the period . hedge funds and other institutional investors own 65.29 % of the company 's stock . trademark violation warning : `` concert pharmaceuticals downgraded by bidaskclub to hold '' was originally published by watch list news and is the property of of watch list news . if you are reading this news story on another site , it was stolen and republished in violation of us and international copyright & trademark laws . the correct version of this news story can be viewed at pharmaceuticals company profileconcert pharmaceuticals , inc is a clinical-stage biopharmaceutical company . ",
        "the company is engaged in the discovery and development of small molecule drugs . the company operates through the development of pharmaceutical products on its own behalf or in collaboration with others . the company 's deuterated chemical entity platform , has potential across various therapeutic areas .   "
    ]
}